Transgene (TNG) Aktievy
Transgene SA är ett bioteknikföretag som designar och utvecklar terapeutiska vacciner och onkolytiska virus för behandling av cancer i Frankrike. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 0/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
TNG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Transgene SA Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | €0.76 |
| 52 veckors högsta | €1.50 |
| 52 veckors lägsta | €0.73 |
| Beta | 0.71 |
| 1 månads förändring | -9.30% |
| 3 månaders förändring | -1.68% |
| 1 års förändring | -21.38% |
| 3 års förändring | -61.37% |
| 5 års förändring | -70.95% |
| Förändring sedan börsintroduktionen | -98.31% |
Senaste nyheter och uppdateringar
TNG: Phase II Head And Neck Data Will Drive Future Repricing
Analysts have adjusted their fair value estimate for Transgene stock to €1.10 per share. This change reflects updated assumptions on discount rates, profit margins and a significantly higher future P/E multiple in their models.TNG: Phase II Head And Neck Progress Will Drive Future Repricing
Analysts have kept their price target for Transgene broadly steady at €1.10, citing updated assumptions around discount rates, profit margins and future P/E that refine rather than overhaul their valuation view. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed €1.10 target as a signal that core valuation inputs such as discount rates and profit assumptions still support the current framework rather than requiring a reset.TNG: Phase I Head And Neck Data Will Support Future Repricing
Analysts have adjusted their price target on Transgene to €1.10, based on updated assumptions that include a very large change in revenue growth expectations, a lower discount rate, and a revised future P/E of about 13x. Analyst Commentary Bullish Takeaways Bullish analysts view the revised €1.10 price target and the use of a P/E of about 13x as a sign that current assumptions aim to better align valuation with the risk profile investors are willing to accept.Recent updates
TNG: Phase II Head And Neck Data Will Drive Future Repricing
Analysts have adjusted their fair value estimate for Transgene stock to €1.10 per share. This change reflects updated assumptions on discount rates, profit margins and a significantly higher future P/E multiple in their models.TNG: Phase II Head And Neck Progress Will Drive Future Repricing
Analysts have kept their price target for Transgene broadly steady at €1.10, citing updated assumptions around discount rates, profit margins and future P/E that refine rather than overhaul their valuation view. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed €1.10 target as a signal that core valuation inputs such as discount rates and profit assumptions still support the current framework rather than requiring a reset.TNG: Phase I Head And Neck Data Will Support Future Repricing
Analysts have adjusted their price target on Transgene to €1.10, based on updated assumptions that include a very large change in revenue growth expectations, a lower discount rate, and a revised future P/E of about 13x. Analyst Commentary Bullish Takeaways Bullish analysts view the revised €1.10 price target and the use of a P/E of about 13x as a sign that current assumptions aim to better align valuation with the risk profile investors are willing to accept.TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have kept their price target on Transgene broadly in line with prior views, with only marginal tweaks to inputs like the discount rate and long term P/E assumptions, indicating a steady valuation framework in euro terms rather than a meaningful reset. What's in the News Transgene released a preprint on medRxiv covering clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic cancer vaccine for operable head and neck cancers (medRxiv).TNG: Phase I Head And Neck Vaccine Data Will Support Future Repricing
Analysts have maintained their price target for Transgene at €1.10, reflecting largely stable assumptions on the discount rate, revenue trends, margins, and future P/E expectations. What's in the News Transgene released a preprint on medRxiv with a comprehensive analysis of clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine.TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have reduced their price target for Transgene to €1.10 from €2.00, reflecting updated assumptions that include a higher discount rate, lower revenue growth expectations, improved profit margin and a lower future P/E multiple. What's in the News Transgene released a preprint on medRxiv detailing clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine for operable head and neck cancers (medRxiv preprint).
TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential
Analysts have adjusted their price target on Transgene slightly, reflecting updated assumptions for a discount rate, revenue growth of 33.57% and a forward P/E of 27.97x, while keeping fair value at €1.10. This suggests a more finely tuned view of the company’s risk and earnings profile rather than a major shift in outlook.TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential
Analysts have adjusted their price target for Transgene, citing updated assumptions on discount rate, revenue growth, profit margin and a lower future P/E multiple as key drivers of the change in valuation. The new target is presented in line with a fair value estimate of €1.10 per share.TNG: Clinical Progress And Capital Raise Will Support Future Upside
Analysts have adjusted their price target for Transgene, citing updated assumptions that keep fair value at €1.10 while reflecting different views on revenue growth, profit margins, and a higher future P/E multiple. What's in the News Preprint publication on medRxiv shares clinical and translational data from the Phase I part of Transgene's randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine, with the manuscript also submitted to a peer reviewed journal for evaluation (Product related announcement).TNG: Pipeline Progress And Stronger Balance Sheet Will Drive Future Upside
Analysts have moderately reduced their price target on Transgene, cutting fair value by about 20 percent to approximately 1.10 euros. They have incorporated slower expected revenue growth, a higher discount rate, and a more balanced, though significantly improved, long term profit margin outlook into their models.Is Transgene (EPA:TNG) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines
Progress in TG4050 trials could establish Transgene as a leader in cancer vaccines, boosting reputation and revenue opportunities.Is Transgene (EPA:TNG) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term
One thing we could say about the analysts on Transgene SA ( EPA:TNG ) - they aren't optimistic, having just made a...Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Last week, you might have seen that Transgene SA ( EPA:TNG ) released its full-year result to the market. The early...Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?
Every investor in Transgene SA ( EPA:TNG ) should be aware of the most powerful shareholder groups. Insiders often own...Aktieägarnas avkastning
| TNG | FR Biotechs | FR Marknad | |
|---|---|---|---|
| 7D | -1.4% | -2.8% | 2.2% |
| 1Y | -21.4% | 246.9% | 4.8% |
Avkastning vs industri: TNG presterade sämre än French Biotechs branschen som gav 246.9 % under det senaste året.
Avkastning vs Marknaden: TNG presterade sämre än French marknaden som gav 4.8 % under det senaste året.
Prisvolatilitet
| TNG volatility | |
|---|---|
| TNG Average Weekly Movement | 4.0% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in FR Market | 11.2% |
| 10% least volatile stocks in FR Market | 2.7% |
Stabil aktiekurs: TNG har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för French.
Volatilitet över tid: TNG s veckovolatilitet ( 4% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1979 | 145 | Alessandro Riva | www.transgene.com |
Transgene SA är ett bioteknikföretag som designar och utvecklar terapeutiska vacciner och onkolytiska virus för behandling av cancer i Frankrike. Bolaget är involverat i utvecklingen av TG4050, ett terapeutiskt vaccin som befinner sig i klinisk fas II-prövning för behandling av äggstockscancer samt huvud- och halscancer; TG4001, ett terapeutiskt vaccin som befinner sig i klinisk fas II-prövning för behandling av cancerformer som är positiva för humant papillomvirus (HPV 16); TG6002, ett onkolytiskt virus som befinner sig i klinisk fas I/IIa för behandling av solida tumörer, inklusive gastrointestinalt adenokarcinom; och BT-001, ett onkolytiskt virus som befinner sig i klinisk fas I/II för behandling av solida tumörer. Bolaget utvecklar också TG6050 för behandling av icke-småcellig lungcancer, som befinner sig i klinisk fas 1-studie, och Pexa-Vec, ett onkolytiskt virus för behandling av solida tumörer.
Transgene SA Sammanfattning av grunderna
| TNG grundläggande statistik | |
|---|---|
| Börsvärde | €208.42m |
| Vinst(TTM) | -€37.52m |
| Intäkter(TTM) | €7.21m |
Är TNG övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| TNG resultaträkning (TTM) | |
|---|---|
| Intäkter | €7.21m |
| Kostnad för intäkter | €33.90m |
| Bruttovinst | -€26.69m |
| Övriga kostnader | €10.84m |
| Intäkter | -€37.52m |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
Sep 24, 2026
| Vinst per aktie (EPS) | -0.14 |
| Bruttomarginal | -370.12% |
| Nettovinstmarginal | -520.44% |
| Skuld/egenkapitalförhållande | 1.7% |
Hur har TNG utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/15 12:13 |
| Aktiekurs vid dagens slut | 2026/06/15 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Transgene SA bevakas av 5 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Arsene Guekam | CIC Market Solutions (ESN) |
| Michael Thomas Cooper | Edison Investment Research |
| Martial Descoutures | ODDO BHF Corporate & Markets |